TLRY

Tilray Brands Inc. (TLRY) | Rumor.io

Tilray Brands

TLRY

Attention (50-day avg)0.03%

Attention rank (50-day avg)#220

Bullish sentiment (50-day avg)80%

Price to earnings ratio-3.69

Market capitalization564.5M

Earnings per share-1.09

Dividend yield (TTM)—

Revenue (annual)915.5M

Net income (annual)-105.2M

Social

What share of all stock conversation is about TLRY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% 0	0.08% +0.05	0.03% +0.01	0.04% -0.06

Sep 29

TLRY's ATM closed announcement is expected soon, potentially with a blowout quarter and a possible pharma partnership announcement.
The ALJ process may stall for a year and get litigated into the 2028 election, delaying a potential Schedule III ruling for Tilray.
The VA's standard federal procurement process for international suppliers of Tilray products may take several weeks to months to finalize, with security and supply agreements expected to move through negotiation and formal announcement between September and November 2026.

Generated by AI

Sentiment

Of the messages about TLRY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	73.64% -1.18	77.88% -2.28	74.77% -12.17	80.7% +0.5
Bearish	26.36% +1.18	22.12% +2.28	25.23% +12.17	19.3% -0.5

Bullish· Sep 29

Tilray Brands, Inc. ($TLRY) is expected to announce a blowout quarter with possible pharma partnership news, driving the stock up.
The company's longest legs in the sector make it a prime candidate for a significant price increase, with some expecting $20 per share.
Institutional investors are taking advantage of low prices to buy in, potentially padding the votes needed for the CEO to remain in position.

Bearish· Sep 24

The bearish sentiment towards Tilray Brands, Inc. is driven by concerns over the company's control by bears and potential dilution of shares by CEO Irwin Simon.
The shorts are focusing on US cannabis, and the company's inability to break down despite rising short interest, with some traders expecting a price drop.
The company's financial performance is under scrutiny, with some highlighting its accumulated deficit of $5B and low international cannabis revenue of $85M, raising concerns about its long-term viability.

Generated by AI

Topics

Of the messages about TLRY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	32.72%	33.14%	17.9%
Technical Analysis	57.89%	33.43%	26.02%	20.95%
Announcements	21.05%	0.78%	3.87%	28.53%
Macro	0%	33%	33.19%	23.53%
Controversies	21.05%	0.07%	0.35%	2.7%
Earnings	0%	0%	3.44%	6.4%

Earnings· Jul 28

Tilray Brands, Inc. reported record fiscal 2026 revenue of $915.5M, up 11% YoY, with record gross profit of $260.4M and adjusted EBITDA of $61.1M.
The company beat earnings estimates with an adjusted EPS of $0.05, compared to an estimate of -$0.01, and reported a 25.47% increase in quarterly sales to $281.7M.
Despite the beat, Tilray's GAAP net loss was $105.2M for the full year, and the company's consolidated gross margin declined to 28% from 29% YoY, with its beverage gross margin falling to 36% from 39%.

Analysts· Aug 25

Jefferies raised the price target for Tilray Brands, Inc. (TLRY) to $2.00 from $1.50, citing potential benefits from a US federal policy shift that could reschedule cannabis from Schedule I to Schedule III.
Tilray's stock price surged 20% after the price target upgrade, with analysts noting the company's brand strength, scale, and balance sheet position it for potential cannabis market opportunities.
A strong presence in the international medical cannabis market, diversified revenue streams, and potential regulatory changes are seen as positive catalysts for Tilray's stock performance.

Announcements· Apr 27

Tilray Brands, Inc. ($TLRY) has raised $180M, which is speculated to be for a massive US MSO acquisition following the rescheduling of cannabis to Schedule III.
The company is well-positioned to participate in the US regulated medical cannabis market, with a proven track record of operating at scale in highly-regulated markets globally.
Tilray's acquisition of a majority position in MedMen Enterprises' debt in 2021 provided a strategic foothold for future US market entry pending federal legalization.

Controversies· Apr 23

Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana to Schedule III, reducing legal risk and removing punitive tax burdens for cannabis companies.
Major banks are expected to remain cautious, as cannabis will still be technically federally illegal, with full access likely requiring the passage of the SAFER Banking Act.
Tilray's lack of FDA-approved cannabis drugs and state medical marijuana licenses may hinder its benefits from the reclassification, unlike companies like Trulieve in Florida.

Macro· May 1

The US Senate is working to delist marijuana from the CSA, which could lead to federal legalization and significant market cap increases for companies like TLRY and CGC.
TLRY has FDA and GMP certifications, allowing it to export 40% cheaper cannabis into the US upon rescheduling, and has infrastructure set up in 50 states to sell THC/CBD drinks.
The DEA's potential strict regulations on marijuana could hinder its growth, and TLRY's global presence, especially with Germany's legalization, could help it grow exponentially despite these challenges.

Technical Analysis· Sep 23

The post by Elliott Wellen analyzes the recent 4% price increase in TLRY, discussing the chart structure, Fibonacci support zones, and key price levels.
A Nasdaq rule may trigger a 38.2% to 50% retracement, potentially leading to a market maker dump on the bid to restore order.
A bullish signal for TLRY would be a weekly close above the 0.5 Fibonacci level, which is considered a desirable technical indicator.

Generated by AI

Community

Of the messages about TLRY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	91.05%	89.23%	88.35%	74.58%
Newcomers	8.95%	10.77%	11.65%	25.42%

Regulars· Sep 29

The regulars are anticipating an ATM announcement on October 8th, potentially accompanied by a pharma partnership announcement, which could lead to a blowout quarter and a stock price of $20.
The regulars are concerned about the potential delay in the DEA's Schedule III case, but not a bearish ruling, and are awaiting the GAO report's consideration by Julius, which could impact the case's timing.
The regulars are discussing the performance of the stock, with one regular highlighting the significant price drop over the past year (-79%) and another joking about the incompetent CEOs, Zack from SNDL and Simon from TLRY.

Newcomers· Sep 24

Many newcomers are interested in buying or selling Tilray stocks, with some offering to sell their existing shares.
Some users are concerned about the influence of short sellers, particularly Citadel, on the stock price and the company's management.
There is speculation about the potential impact of Tilray CEO Irwin Simon's leadership on the company's future, with some users advocating for his removal.

Generated by AI

News

Tilray Brands Inc. stock falls Tuesday, underperforms market

14h agoMarketWatch

Give BrewDog ‘second chance’ says new owner as it invests £50m

US cannabis and drinks firm Tilray, which took over in March, says it will improve beers, pubs and working conditions

16h agoThe Guardian

Tilray Brands Inc. stock falls Monday, underperforms market

1d agoMarketWatch

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $4.02, representing a -2.66% change from its previous close.

1d agoYahoo Finance UK

Tilray Brands Inc. stock rises Friday, outperforms market

4d agoMarketWatch

Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026

NEW YORK and LONDON and LEAMINGTON, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, hospitality and wellness industries, today announced that the Company will release its financial results for the first fiscal quarter ended August 31, 2026, before the financial markets open on Thursday, October 8, 2026. Live Conference Call and

4d agoYahoo Finance

Also Discussed

Investors talking about TLRY also mention

#	Name	Attention
1	Canopy Growth CorporationCGC	0%-0.01
2	Aurora Cannabis Inc.ACB	0%-0.01
3	AdvisorShares Pure US Cannabis ETFMSOS	0.49%-0.18
4	Cronos Group Inc.CRON	0%0
5	Organigram Global Inc.OGI	0.01%new
6	HEXO - HEXO Corp.	——
7	Village Farms International Inc.VFF	0.01%-0.01
8	Amplify Alternative Harvest ETFMJ	0%new
9	AdvisorShares MSOS Daily Leveraged ETFMSOX	0.15%-0.05
10	SNDL Inc.SNDL	0.01%+0

Tilray Brands Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Tilray Brands Inc. is a global lifestyle consumer products company focused on cannabis, beverage alcohol, wellness, and distribution. Tilray Brands develops, cultivates, processes, and markets medical and adult-use cannabis products, while also offering hemp-based wellness goods, pharmaceutical distribution services, and a portfolio of craft beverages and spirits. The company serves a broad customer base that includes retailers, wholesalers, patients, healthcare professionals, and consumers across multiple international markets. Its business is organized around four main areas: Cannabis, Beverage, Distribution, and Wellness, allowing it to operate across regulated and consumer-focused categories. Tilray Brands Inc. plays a notable role in the evolving consumer products landscape by combining plant-based wellness offerings with beverage and branded goods under one diversified platform.

Website

Location

265 Talbot Street West

Leamington, ON, N8H 5L4

Canada

Social

What share of all stock conversation is about TLRY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% 0	0.08% +0.05	0.03% +0.01	0.04% -0.06

Sep 29

TLRY's ATM closed announcement is expected soon, potentially with a blowout quarter and a possible pharma partnership announcement.
The ALJ process may stall for a year and get litigated into the 2028 election, delaying a potential Schedule III ruling for Tilray.
The VA's standard federal procurement process for international suppliers of Tilray products may take several weeks to months to finalize, with security and supply agreements expected to move through negotiation and formal announcement between September and November 2026.

Generated by AI

Sentiment

Of the messages about TLRY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	73.64% -1.18	77.88% -2.28	74.77% -12.17	80.7% +0.5
Bearish	26.36% +1.18	22.12% +2.28	25.23% +12.17	19.3% -0.5

Bullish· Sep 29

Tilray Brands, Inc. ($TLRY) is expected to announce a blowout quarter with possible pharma partnership news, driving the stock up.
The company's longest legs in the sector make it a prime candidate for a significant price increase, with some expecting $20 per share.
Institutional investors are taking advantage of low prices to buy in, potentially padding the votes needed for the CEO to remain in position.

Bearish· Sep 24

The bearish sentiment towards Tilray Brands, Inc. is driven by concerns over the company's control by bears and potential dilution of shares by CEO Irwin Simon.
The shorts are focusing on US cannabis, and the company's inability to break down despite rising short interest, with some traders expecting a price drop.
The company's financial performance is under scrutiny, with some highlighting its accumulated deficit of $5B and low international cannabis revenue of $85M, raising concerns about its long-term viability.

Generated by AI

Topics

Of the messages about TLRY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	32.72%	33.14%	17.9%
Technical Analysis	57.89%	33.43%	26.02%	20.95%
Announcements	21.05%	0.78%	3.87%	28.53%
Macro	0%	33%	33.19%	23.53%
Controversies	21.05%	0.07%	0.35%	2.7%
Earnings	0%	0%	3.44%	6.4%

Earnings· Jul 28

Tilray Brands, Inc. reported record fiscal 2026 revenue of $915.5M, up 11% YoY, with record gross profit of $260.4M and adjusted EBITDA of $61.1M.
The company beat earnings estimates with an adjusted EPS of $0.05, compared to an estimate of -$0.01, and reported a 25.47% increase in quarterly sales to $281.7M.
Despite the beat, Tilray's GAAP net loss was $105.2M for the full year, and the company's consolidated gross margin declined to 28% from 29% YoY, with its beverage gross margin falling to 36% from 39%.

Analysts· Aug 25

Jefferies raised the price target for Tilray Brands, Inc. (TLRY) to $2.00 from $1.50, citing potential benefits from a US federal policy shift that could reschedule cannabis from Schedule I to Schedule III.
Tilray's stock price surged 20% after the price target upgrade, with analysts noting the company's brand strength, scale, and balance sheet position it for potential cannabis market opportunities.
A strong presence in the international medical cannabis market, diversified revenue streams, and potential regulatory changes are seen as positive catalysts for Tilray's stock performance.

Announcements· Apr 27

Tilray Brands, Inc. ($TLRY) has raised $180M, which is speculated to be for a massive US MSO acquisition following the rescheduling of cannabis to Schedule III.
The company is well-positioned to participate in the US regulated medical cannabis market, with a proven track record of operating at scale in highly-regulated markets globally.
Tilray's acquisition of a majority position in MedMen Enterprises' debt in 2021 provided a strategic foothold for future US market entry pending federal legalization.

Controversies· Apr 23

Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana to Schedule III, reducing legal risk and removing punitive tax burdens for cannabis companies.
Major banks are expected to remain cautious, as cannabis will still be technically federally illegal, with full access likely requiring the passage of the SAFER Banking Act.
Tilray's lack of FDA-approved cannabis drugs and state medical marijuana licenses may hinder its benefits from the reclassification, unlike companies like Trulieve in Florida.

Macro· May 1

The US Senate is working to delist marijuana from the CSA, which could lead to federal legalization and significant market cap increases for companies like TLRY and CGC.
TLRY has FDA and GMP certifications, allowing it to export 40% cheaper cannabis into the US upon rescheduling, and has infrastructure set up in 50 states to sell THC/CBD drinks.
The DEA's potential strict regulations on marijuana could hinder its growth, and TLRY's global presence, especially with Germany's legalization, could help it grow exponentially despite these challenges.

Technical Analysis· Sep 23

The post by Elliott Wellen analyzes the recent 4% price increase in TLRY, discussing the chart structure, Fibonacci support zones, and key price levels.
A Nasdaq rule may trigger a 38.2% to 50% retracement, potentially leading to a market maker dump on the bid to restore order.
A bullish signal for TLRY would be a weekly close above the 0.5 Fibonacci level, which is considered a desirable technical indicator.

Generated by AI

Community

Of the messages about TLRY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	91.05%	89.23%	88.35%	74.58%
Newcomers	8.95%	10.77%	11.65%	25.42%

Regulars· Sep 29

The regulars are anticipating an ATM announcement on October 8th, potentially accompanied by a pharma partnership announcement, which could lead to a blowout quarter and a stock price of $20.
The regulars are concerned about the potential delay in the DEA's Schedule III case, but not a bearish ruling, and are awaiting the GAO report's consideration by Julius, which could impact the case's timing.
The regulars are discussing the performance of the stock, with one regular highlighting the significant price drop over the past year (-79%) and another joking about the incompetent CEOs, Zack from SNDL and Simon from TLRY.

Newcomers· Sep 24

Many newcomers are interested in buying or selling Tilray stocks, with some offering to sell their existing shares.
Some users are concerned about the influence of short sellers, particularly Citadel, on the stock price and the company's management.
There is speculation about the potential impact of Tilray CEO Irwin Simon's leadership on the company's future, with some users advocating for his removal.

Generated by AI

Tilray Brands

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 24

Earnings· Jul 28

Analysts· Aug 25

Announcements· Apr 27

Controversies· Apr 23

Macro· May 1

Technical Analysis· Sep 23

Regulars· Sep 29

Newcomers· Sep 24

Tilray Brands Inc. stock falls Tuesday, underperforms market

Give BrewDog ‘second chance’ says new owner as it invests £50m

Tilray Brands Inc. stock falls Monday, underperforms market

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

Tilray Brands Inc. stock rises Friday, outperforms market

Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026

Also Discussed

Tilray Brands Inc.

Company Information

Location

Tilray Brands Inc. stock falls Tuesday, underperforms market

Give BrewDog ‘second chance’ says new owner as it invests £50m

Tilray Brands Inc. stock falls Monday, underperforms market

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

Tilray Brands Inc. stock rises Friday, outperforms market

Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 24

Earnings· Jul 28

Analysts· Aug 25

Announcements· Apr 27

Controversies· Apr 23

Macro· May 1

Technical Analysis· Sep 23

Regulars· Sep 29

Newcomers· Sep 24